Hepion Pharmaceuticals (HEPA) Institutional Ownership $0.28 -0.01 (-2.57%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.28 0.00 (-1.26%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Hepion Pharmaceuticals (NASDAQ:HEPA)CurrentInstitutional OwnershipPercentage17.24%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$14.19MNumber ofInstitutional Sellers(last 12 months)0 Get HEPA Insider Trade Alerts Want to know when executives and insiders are buying or selling Hepion Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data HEPA Institutional Buying and Selling by Quarter Hepion Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2024Anson Funds Management LP231,849$155K0.0%N/A3.331% 8/15/2024Armistice Capital LLC516,000$526K0.0%+32.3%9.428% 2/13/2024Armistice Capital LLC418,000$1.35M0.0%+5.1%9.631% 11/15/2023Armistice Capital LLC397,607$1.98M0.0%N/A10.360% 5/1/2023Virtu Financial LLC53,501$42K0.0%+152.8%0.070% 11/7/2022Virtu Financial LLC67,802$34K0.0%+195.6%0.089% 10/13/2022PVG Asset Management Corp107,915$55K0.2%N/A0.142% 8/12/2022Ikarian Capital LLC410,189$235K0.0%-29.5%0.538% 2/4/2022 Envestnet Asset Management Inc.72,027$82K0.0%+87.5%0.094% 2/2/2022PVG Asset Management Corp100,089$114K0.4%+92.5%0.131% Get the Latest News and Ratings for HEPA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/10/2021PVG Asset Management Corp51,989$80K0.2%-72.6%0.068% 11/9/2021BlackRock Inc.1,634,012$2.50M0.0%-1.0%2.144% 11/5/2021PNC Financial Services Group Inc.39,034$60K0.0%N/A0.051% 10/13/2021Asset Management Corp IL ADV133,500$204K0.1%+45.9%0.175% 9/17/2021Virtu Financial LLC113,869$225K0.0%-36.4%0.149% 8/18/2021Ikarian Capital LLC1,365,059$2.70M0.2%N/A1.791% 8/17/2021PVG Asset Management Corp189,616$375K1.2%+1,241.0%0.249% 8/17/2021Boothbay Fund Management LLC155,069$307K0.0%N/A0.203% 8/16/2021Morgan Stanley91,106$180K0.0%+197,956.5%0.120% 8/16/2021State Street Corp322,716$639K0.0%N/A0.423% 8/16/2021Goldman Sachs Group Inc.68,399$135K0.0%N/A0.090% 8/13/2021Altium Capital Management LP446,000$883K0.2%N/A0.585% 8/13/2021Geode Capital Management LLC651,318$1.29M0.0%+10.6%0.854% 8/11/2021BlackRock Inc.1,649,929$3.27M0.0%-3.9%2.165% 8/6/2021Asset Management Corp IL ADV91,500$181K0.1%N/A0.120% 8/4/2021 Envestnet Asset Management Inc.92,919$184K0.0%+256.9%0.122% 8/2/2021Advisor Group Holdings Inc.17,751$35K0.0%+94.9%0.023% 8/2/2021McAdam LLC55,978$86K0.0%+52.8%0.073% 5/19/2021Virtu Financial LLC179,030$329K0.0%N/A0.235% 5/14/2021PVG Asset Management Corp14,140$26K0.1%N/A0.019% 5/13/2021Renaissance Technologies LLC157,500$290K0.0%-52.1%0.207% 5/13/2021 Bank of New York Mellon Corp48,602$89K0.0%+18.7%0.064% 5/12/2021Northern Trust Corp145,515$268K0.0%+129.5%0.191% 5/12/2021Geode Capital Management LLC588,718$1.08M0.0%+190.6%0.772% 5/12/2021UBS Group AG68,202$125K0.0%+10,794.9%0.089% 5/11/2021Rockefeller Capital Management L.P.20,000$36K0.0%N/A0.026% 5/10/2021GSA Capital Partners LLP160,775$296K0.0%+80.5%0.211% 5/7/2021BlackRock Inc.1,716,168$3.16M0.0%+43.7%2.251% 5/6/2021Prospera Financial Services Inc31,300$58K0.0%-20.4%0.041% 5/6/2021Meitav Dash Investments Ltd.44,000$81K0.0%N/A0.058% Gold Alert: The Truth About Fort Knox Is Coming (Ad)Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.Click here now before the biggest gold run in decades kicks off.5/4/2021 Envestnet Asset Management Inc.26,037$48K0.0%N/A0.034% 4/28/2021 JGP Wealth Management LLC15,000$28K0.0%N/A0.020% (Data available from 1/1/2016 forward) HEPA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of HEPA shares? During the previous two years, the following institutional investors and hedge funds held shares of Hepion Pharmaceuticals shares: Armistice Capital LLC ($526K), Anson Funds Management LP ($155K).Learn more on HEPA's institutional investors. What percentage of Hepion Pharmaceuticals stock is owned by institutional investors? 17.24% of Hepion Pharmaceuticals stock is owned by institutional investors. Learn more on HEPA's institutional investor holdings. Which institutional investors have been buying Hepion Pharmaceuticals stock? The following institutional investors have purchased Hepion Pharmaceuticals stock in the last 24 months: Armistice Capital LLC ($544K), and Anson Funds Management LP ($231.85K). How much institutional buying is happening at Hepion Pharmaceuticals? Institutional investors have bought a total of 775,849 shares in the last 24 months. This purchase volume represents approximately $116.70M in transactions. Related Companies IMNN Major Shareholders NERV Major Shareholders RLYB Major Shareholders RLMD Major Shareholders ABVC Major Shareholders LSB Major Shareholders ATHA Major Shareholders BGXX Major Shareholders FLGC Major Shareholders BCDA Major Shareholders This page (NASDAQ:HEPA) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.